Therapeutic Asset Ratings

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Olutasidenib Acute Myeloid Leukemia	M.D. Anderson Cancer Center	P4	BB (67)
Orlistat Type 2 Diabetes Mellitus	Affiliated Hospital of Nantong University	P4	BB (67)
Oxaliplatin Cancer	Sixth Affiliated Hospital, Sun Yat-sen University	P4	BB (67)
Oxytocin Obesity Disorder	University Hospital, Gentofte, Copenhagen	P4	BB (67)
Pertuzumab Breast Neoplasm	Merck Sharp & Dohme LLC	P4	BB (67)
Pramipexole Bipolar Disorder	Daniel Lindqvist	P4	BB (67)
Prednisolone Castration-Resistant Prostate Carcinoma	Ding-Wei Ye	P4	BB (67)
Prednisolone Metastatic Prostate Carcinoma	BioNTech SE	P4	BB (67)
Prednisone Angioimmunoblastic T-Cell Lymphoma	Shanghai Jiao Tong University School of Medicine	P4	BB (67)
Prednisone Skin Cancer	Dana-Farber Cancer Institute	P4	BB (67)
Propofol Alzheimer Disease	Nyree Penn	P4	BB (67)
Propofol Stroke Disorder	Johns Hopkins University	P4	BB (67)
Prucalopride Inflammatory Bowel Disease	Region Skane	P4	BB (67)
Ramifentanyl Cardiovascular Disorder	Helse Fonna	P4	BB (67)
Ropivacaine Breast Neoplasm	Fudan University	P4	BB (67)
Ruxolitinib Graft Versus Host Disease	Jonathan Brammer	P4	BB (67)
Sertraline Bipolar Depression	Dr. Inge Winter	P4	BB (67)
Simvastatin Stroke Disorder	Northern California Institute of Research and Education	P4	BB (67)
Suvorexant Insomnia	Mayo Clinic	P4	BB (67)
Talquetamab Plasma Cell Myeloma	Anne Louise Tølbøll Sørensen	P4	BB (67)
Teclistamab Plasma Cell Myeloma	Anne Louise Tølbøll Sørensen	P4	BB (67)
Tenofovir Disoproxil Fumarate Chronic Hepatitis B Virus Infection	Ningbo No.2 Hospital	P4	BB (67)
Tirzepatide Psoriasis	Eli Lilly and Company	P4	BB (67)
Tucidinostat Extranodal Nasal NK/T Cell Lymphoma	Ruijin Hospital	P4	BB (67)
Tunlametinib Melanoma	Fudan University	P4	BB (67)

Showing 1651 to 1675 of 42,301 assets

PreviousPage 67 of 1693Next